1) -Averette HE, Nguyen HN (1994) The role of prophylactic oophorectomy in cancer prevention. Gynecologic Oncology, 55: S38-S41

2) -Utian WH, GoldfarbJ. Ovarian management during radical hysterectomy in the premenopausal patient. Obstet Gynecol 1993;82(6):1042

3) -Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer: A prospective study. JAMA, 270, 23: 2813-2818

4) -Prazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R. (1993) Hysterectomy, oophorectomy, and subsequent ovarian cancer. Obstet Gynecol 81:363-366

5) -Nguyen HN, Averette HE, Janicek M. (1994) Ovarian carcinoma: A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer 74, 2:545-555

6) -Herbst AL. (1994) The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J ObstetGynecol 170, 4:1099-1107

7) -Cutler WB, (1990) Hysterectomy Before and After HarperCollins, NY.pp 40-41 and 256-257

8) -Cutler WB (1997) Pheromonal Modulation of Brain and Behavior, an invited chapter, under review in Hormonal Modulation of Brain and Behavior, American Psychiatric Press.

9) -Cutler WB and Garcia CR. (1984) The Medical Management of the Menopause and Premenopause: Their Endocrinologic Basis. Lippincott Co., Philadelphia, PA.

10) -Eggert-Kruse W, Kruse W, Rohr G, Muller S & others (1994) Hormone profile of elderly women and potential modifiers. Geburtshilfe Frauenheilkd 54, 6:321-31

11) -Carlstrom K, Brody S, Lunell NO, Lagrelius A, Mollerstrom G, Pousette A, Rannevik G, Stege R, von Schoultz B (1988) Dehydroepiandrosterone in serum: Differences related to age and sex. Maturitas 10:297-306

12) -Cumming DC, Rebar RW, Hopper BR, Yen SSC (1982) Evidence or an influence of the ovary on circulating dehydroepiandrosterone sulfate levels. J of Clinical Endocrinology & Metabolism 54, 5:1069-1071

13) -Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL. (1988) Dehydroepiandrosterone and structural analogs: A new class of cancer chemopreventive agents. Advances in Cancer Research 51:391-425

14) -Mason BH, Holdaway IM, Skinner SJ, Kay RG (1994) The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival. Breast Cancer Res Treat 32, 2:203-12

15) -Barrett-Connor E, Khaw K-t, Yen S (1986) A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. New England J of Med, 315:1519-1524

16) -Mortola JF and Yen SC (1990) The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 696-704.

17) -Barrett-Connor E, Goodman-Gruen D (1995) Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Dept of Family & Preventive Medicine 91, 6:1757-60

18) -Nordin BEC, Robertson A, Seamark RF, Bridges A, Philcox JC, Need AG, Horowitz M, Morris HA, Deam S. (1985) The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J of Clin Endocrinology & Metabolism 60:651-657

19) -Bodine PV, Riggs BL, Spelsberg TC (1995) Regulation of c-fos expression and TGF-beta production by gonadal and adrenal androgens in normal human osteoblastic cells. J Steroid Biochem Mol Biol 52, 2:149-58

20) -Bologna I, Sharma J, Roberts E (1987) Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocyctic differentiation in brain cell cultures. J of Neuroscience Research 17:225-234

21) -Sunderland T, Merril CR, Harrington MG, Lawlor BA, Molchan SE, Martinez R, Murphy DL. (1989) Reduced plasma dehydroepiandrosterone concentrations in alzheimer's disease. Lancet pg 570

22) -Casson P, Faquin L, Stentz F, Straughn A, Andersen R, Abraham G, Buster J (1995) Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil/Steril 63:1027-1037

23) -Goldstein S, Suramanyam B, Snyder J, Beller U, Raghavendra BN, Beckman EM(1989) The postmenopausal cystic adnexal mass: The potential role of ultrasound in conservative management. Obstet Gynecol 73:8-10

24)-Weiner Z, Thaler I, Beck D, Rotten S, Deutsch M, Brandes J. (1992) Differentiating malignant from benign ovarian tumors with transvaginal colorflow imaging. Obstet Gynecol 79:159-162

25) -Brumstead JR, Blackman JA, Badger GJ, Riddick DH (1996) Hysteroscopy versus hysterectomy for the treatment of abnormal uterine bleeding: A comparison of cost. Fertility and Sterility 65:310-316